Fecal microbiota transplant as a new therapeutic in the management of type 2 Diabetes Mellitus
DOI:
https://doi.org/10.56294/saludcyt2025960Keywords:
Type 2 Diabetes Mellitus, Intestinal Microbiota, Eubiosis, Dysbiosis, Public Health, Endocrine-Metabolic DiseaseAbstract
Introduction Type 2 diabetes mellitus (DM2) is a global public health problem, and is one of the main causes of disability, premature death and complications, resulting from poor glycemic control, poor monitoring and underlying chronic pathologies. The budget for care is increasingly scarce, which is why there is a need to find new cost-effective therapeutic options that offer multiple benefits and contribute to achieving therapeutic objectives.
Objective: to determine the efficacy of fecal microbiota transplantation as a new therapy in the management of type 2 diabetes.
Results: In the literature review of both human and animal models using FMT, a reduction in blood glucose values, body mass index (BMI), glycosylated hemoglobin (HbA1c), systolic blood pressure, triglycerides and total cholesterol is reported, improving cost-effectiveness in treatment.
Conclusion: FTM is an excellent cost-effective alternative or complementary to conventional treatment of type 2 DM; the benefits are significant in terms of therapy and budget reduction in health systems, however, in developing countries its implementation is not feasible.
References
American Diabetes Professional Association Practice Committee. 2. Diagnosis and Classificationsof Diabetes: Standards of Care. 2024. 1(47): S20–42. Doi: 10.2337/dc24-S002.
Organización Panamericana de la Salud. Organización Panamericana de la Salud [Internet]. 2023 [cited 2024 Feb 16]. Disponible en: https://www.paho.org/es/temas/diabetes.
Qiu B, Liang JX, Li C. Effects of fecal microbiota transplantation in metabolic syndrome: A metaanalysis of randomized controlled trials. 2023;18(7). Doi: 10.1371/journal.pone.0288718.
International Diabetes Federation. Atlas de la Diabetes de la FID. 2023 [cited 2024 Feb 12]. Disponible en: https://diabetesatlas.org/atlas-reports/
Castillo Y., Acuña M., Pinargote F. Factores de riesgos diabetes Mellitus tipo 2 en población urbana. Rev. Arbitrada Interdisciplinaria de Ciencias de la Salud y Vida. 2020;4(8):64. Doi https://doi.org/10.35381/s.v.v4i8.955
Crudele L., Gadaleta R., Cariello M, Moschetta A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. Rev. BioMedicine-Elseiver.2023; 97(104821): 1-13- Doi: https://doi.org/10. 1016/j.ebiom.2023. 104821.
Coello G., Gallegos D. La carga económica de la diabetes para los pacientes y sus familias en el Ecuador. Universidad Técnica de Ambato. 2018 [citado el 13 de febrero del 2024]; 19:18–20. Doi: https://doi.org/10.31164/bcoyu.19.2018.679
Salazar Y. El costo de la Diabetes en las vidas y en la economía. Primicias.ec. 2023. 17;1–5[citado el 20 de febrero del 2024]. Disponible en: https://www.primicias.ec/noticias/firmas/prevencion-diabetes-enfermedad-muerte/
Wang H, Lu Y, Yan Y, Tian S, Zheng D, Leng D, et al. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets. Rev. Cell Infect Microbiol. 2020;9(455).DOI 10.3389/fcimb.2019.00455.
Álvarez J., Fernández R., Guarner F., Gueimonde M. et al. Gut microbes and health. Microbiota intestinal y salud. Rev. Gastroenterología y hepatología. 2021. 44(7), 519–535. DOI https://doi.org/10.1016/j.gastrohep.2021.01.009
Martínez Y., Esquivel D., Sánchez J., Neri D., Guardado R. Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era. Rev. Gut Microbes.2022.14(1). DOI: 10.1080/19490976.2022.2111952
Aydin Ö, Nieuwdorp M, Gerdes V. The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. Current Medicine Group; 2018. 18(8), 55. DOI: 10.1007/s11892-018-1020-6
Wang H, Lu Y, Yan Y, Tian S, Zheng D, Leng D, et al. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets. Front Cell Infect Microbiol. 2020.9(455). Disponible en: https://doi.org/10.3389/fcimb.2019.00455
Yang Y, Yan J, Li S, Liu M, Han R, Wang Y, et al. Efficacy of fecal microbiota transplantation in type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrine, 84(1), 48–62. https://doi.org/10.1007/s12020-023-03606-1
Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Vol. 8, Microorganisms. MDPI AG; 2020; 8(11):1715. https://doi.org/10.3390/microorganisms8111715
He FF, Li YM. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: A review. Journal of ovarian research, 2020;13(1), 73. Disponible: https://doi.org/10.1186/s13048-020-00670-3
Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y, et al. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. 2021;165. Disponible: https://doi.org/10.1016/j.phrs.2021.105420
Klement RJ, Pazienza V. Impact of different types of diet on gut microbiota profiles and cancer prevention and treatment. Vol. 55, Medicina (Lithuania).2019; 55(4), 84. Disponible en: https://doi.org/10.3390/medicina55040084
Craciun CI, Neag MA, Catinean A, Mitre AO, Rusu A, Bala C, et al. The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus. Vol. 10, Biomedicines; 2022. 10(2), 308. Disponible en: https://doi.org/10.3390/biomedicines10020308
Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, et al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clinical Gastroenterology and Hepatology. 2020; 18(4), 855–863.e2. Disponible en: https://doi.org/10.1016/j.cgh.2019.07.006
Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, et al. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil. 2022; 1;28(1):28–42. Disponible en: https://doi.org/10.5056/jnm21221
Rivera-Carranza T, Nájera-Medina O, Azaola-Espinoza A. Fecal microbiota transplantation for the treatment of obesity and its associated comorbidities: A review. Vol. 49, Revista Chilena de Nutricion. Sociedad Chilena de Nutricion Bromatologia y Toxilogica; 2022. p. 238–49. Disponible en :http://dx.doi.org/10.4067/S0717-75182022000200238.
Nicco C, Paule A, Konturek P, Edeas M. From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. Diseases. 2020 Apr 15;8(2):9.Disponible en 8(2), 9. Disponible en: https://doi.org/10.3390/diseases8020009
Su L, Hong Z, Zhou T, Jian Y, Xu M, Zhang X, et al. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation. Sci Rep. 2022 Dec 12(1), 1152. Disponible en: https://doi.org/10.1038/s41598-022-05127-9
Wu Z, Zhang B, Chen F, Xia R, Zhu D, Chen B, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2023 Jan 4;12. Disponible en: https://doi.org/10.3389/fcimb.2022.1089991
Ding D, Yong H, You N, Lu W, Yang X, Ye X, et al. Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients. Front Cell Infect Microbiol. 2022; 25(12). Disponible en: https://doi.org/10.3389/fcimb.2022.820367
Ng Siew C XZJWYMYK. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24- week, double- blind, randomised controlled trial. Gut Microbiota . 2021; 30(1);1–8. Disponible en: https://doi.org/10.1136/gutjnl-2020-323617
Chen L, Guo L, Feng S, Wang C, Cui Z, Wang S, et al. Fecal microbiota transplantation ameliorates type 2 diabetes via metabolic remodeling of the gut microbiota in db/db mice. BMJ Open Diabetes Res Care. 2023 May 30;11(3). Disponible en: https://doi.org/10.1136/bmjdrc-2022-003282
Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. Vol. 51, EBioMedicine. Elsevier B.V.; 2020.Disponible en: https://doi.org/10.1016/j.ebiom.2019.11.051
Waldeyer R BRRWGGIA. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabetes . 2023 (30). Disponible en : https://doi.org/10.1111/dme.12177
Ballesta M. Perez A. Valencia I. Estimación de los costes económicos ocasionados por los pacientes con diabetes mellitus tipo 2 en el área saniaria Cádiz- San Fernando. Actas de Gestión Clínica y Sanitaria. 2023.
Zhou X, Chen R, Cai Y, Chen Q. Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity. 2024 (17)647–59. Disponible en : https://www.dovepress.com/fecal-microbiota-transplantation-a-prospective- treatment-for-type-2-di-peer-reviewed-fulltext-article-DMSO
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Kerly Acosta Cañar, Ricardo Recalde-Navarrete (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
